{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T03:21:47Z","timestamp":1777173707089,"version":"3.51.4"},"publisher-location":"Berlin, Heidelberg","reference-count":134,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783540732587","type":"print"},{"value":"9783540732594","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008]]},"DOI":"10.1007\/978-3-540-73259-4_12","type":"book-chapter","created":{"date-parts":[[2007,12,10]],"date-time":"2007-12-10T16:25:20Z","timestamp":1197303920000},"page":"257-288","source":"Crossref","is-referenced-by-count":6,"title":["Anti-IgE and Other Antibody Targets in Asthma"],"prefix":"10.1007","author":[{"given":"J.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"12_CR1_Ref","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2165\/00063030-200216050-00009","volume":"16","author":"Adis","year":"2002","unstructured":"Adis (2002) Omalizumab. Biodrugs 16:380-386","journal-title":"Biodrugs"},{"key":"12_CR2_Ref","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1084\/jem.180.1.43","volume":"180","author":"P Amiri","year":"1994","unstructured":"Amiri P, Haak-Frendscho M, Robbins K, McKerrow JH, Stewart T, Jardieu P (1994) Antiimmunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med 180:43-51","journal-title":"J Exp Med"},{"key":"12_CR3_Ref","doi-asserted-by":"crossref","unstructured":"Avila PC (2007) Does Anti-IgE Therapy Help in Asthma? Efficacy and Controversies. Annu Rev Med 58","DOI":"10.1146\/annurev.med.58.061705.145252"},{"key":"12_CR4_Ref","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1359-6101(03)00058-3","volume":"14","author":"PJ Barnes","year":"2003","unstructured":"Barnes PJ (2003) Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev 14:511-522","journal-title":"Cytokine Growth Factor Rev"},{"key":"12_CR5_Ref","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1067\/mai.2001.111141","volume":"107","author":"H Bayram","year":"2001","unstructured":"Bayram H, Sapsford RJ, Abdelaziz MM, Khair OA (2001) Effect of ozone and nitrogen dioxide on the release of proinflammatory mediators from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients in vitro. J Allergy Clin Immunol 107:287-294","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR6_Ref","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","volume":"114","author":"LA Beck","year":"2004","unstructured":"Beck LA, Marcotte GV, MacGlashan JD, Togias A, Saini S (2004) Omalizumab-induced reductions in mast cell Fc\u03b5RI expression and function. J Allergy Clin Immunol 114:527-530","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR7_Ref","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/rheumatology\/keh676","volume":"44","author":"AN Bennett","year":"2005","unstructured":"Bennett AN, Wong M, Zain A, Panayi G, Kirkham B (2005) Adalimumab-induced asthma. Rheumatology 44:1199-1200","journal-title":"Rheumatology"},{"key":"12_CR8_Ref","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa050580","volume":"354","author":"MA Berry","year":"2006","unstructured":"Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID (2006) Evidence of a role of tumor necrosis factor {alpha} in refractory asthma. N Engl J Med 354:697-708","journal-title":"N Engl J Med"},{"key":"12_CR9_Ref","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-2285","journal-title":"JAMA"},{"key":"12_CR10_Ref","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1081-1206(10)61221-5","volume":"95","author":"L Borish","year":"2005","unstructured":"Borish L, Chipps B, Deniz Y, Gujrathi S, Zheng B, Dolan C (2005) Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 95:247-253","journal-title":"Ann Allergy Asthma Immunol"},{"key":"12_CR11_Ref","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1067\/mai.2001.115624","volume":"107","author":"LC Borish","year":"2001","unstructured":"Borish LC, Nelson HS, Corren J, Bensch G, Busse WW (2001) Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 107:963-970","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR12_Ref","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1365-2222.2003.01662.x","volume":"33","author":"J Bosson","year":"2003","unstructured":"Bosson J, Stenfors N, Bucht A, Helleday R, Pourazar J, Holgate ST, Kelly FJ, Sandstrom T, Wilson S, Frew AJ, Blomberg A (2003) Ozone-induced bronchial epithelial cytokine expression differs between healthy and asthmatic subjects. Clin Exp Allergy 33:777-782","journal-title":"Clin Exp Allergy"},{"key":"12_CR13_Ref","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1164\/ajrccm.155.6.9196083","volume":"155","author":"L-P Boulet","year":"1997","unstructured":"Boulet L-P, Chapman KR, Cote J, Kalra S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ, Devault A, Fick RB, Cockcroft DW (1997) Inhibitory effects of an AntiIgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155:1835-1840","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR14_Ref","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","volume":"60","author":"J Bousquet","year":"2005","unstructured":"Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60:302-308","journal-title":"Allergy"},{"key":"12_CR15_Ref","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","volume":"125","author":"J Bousquet","year":"2004","unstructured":"Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H (2004) Predicting Response to Omalizumab, an Anti-IgE Antibody, in Patients With Allergic Asthma. Chest 125:1378-1386","journal-title":"Chest"},{"key":"12_CR16_Ref","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jaci.2006.02.039","volume":"117","author":"P Bradding","year":"2006","unstructured":"Bradding P, Walls AF, Holgate ST (2006) The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117:1277-1284","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR17_Ref","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.130.1_suppl.4S","volume":"130","author":"SS Braman","year":"2006","unstructured":"Braman SS (2006) The Global Burden of Asthma. Chest 130:4S-12","journal-title":"Chest"},{"key":"12_CR18_Ref","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0889-857X(02)00101-1","volume":"29","author":"B Bresnihan","year":"2003","unstructured":"Bresnihan B, Cunnane G (2003) Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 29:185-202","journal-title":"Rheum Dis Clin North Am"},{"key":"12_CR19_Ref","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1067\/mai.2001.116436","volume":"108","author":"DH Broide","year":"2001","unstructured":"Broide DH (2001) Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 108:S65-S71","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR20_Ref","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/rmed.2003.1442","volume":"97","author":"R Buhl","year":"2003","unstructured":"Buhl R (2003) Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. Respir Med 97:123-129","journal-title":"Respir Med"},{"key":"12_CR21_Ref","first-page":"27","volume":"11","author":"R Buhl","year":"2004","unstructured":"Buhl R (2004) Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 11:27-34","journal-title":"Curr Opin Pulm Med"},{"key":"12_CR22_Ref","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","volume":"108","author":"W Busse","year":"2001","unstructured":"Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184-190","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR23_Ref","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(97)70202-1","volume":"100","author":"TB Casale","year":"1997","unstructured":"Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann J, Su JQ (1997) Use of an anti-IgE humanized monoclonal antibody in ragweedinduced allergic rhinitis. J Allergy Clin Immunol 100:110-121","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR24_Ref","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaci.2005.09.036","volume":"117","author":"TB Casale","year":"2006","unstructured":"Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, SeyfertMargolis V, Asare A, Bateman K (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117:134-140","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR25_Ref","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/72601","volume":"18","author":"TW Chang","year":"2000","unstructured":"Chang TW (2000) The pharmacological basis of anti-IgE therapy. Nat Biotech 18:157-162","journal-title":"Nat Biotech"},{"key":"12_CR26_Ref","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.prrv.2006.04.007","volume":"7","author":"S Chinn","year":"2006","unstructured":"Chinn S (2006) Obesity and asthma. Paediatr Respir Rev 7:223-228","journal-title":"Paediatr Respir Rev"},{"key":"12_CR27_Ref","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0012-3692(15)51862-X","volume":"130","author":"RT Cohen","year":"2006","unstructured":"Cohen RT, Celedon JC, Hinckson VJ, Ramsey CD, Wakefield DB, Weiss ST, Cloutier MM (2006) Health-Care Use Among Puerto Rican and African-American Children With Asthma. Chest 130:463-471","journal-title":"Chest"},{"key":"12_CR28_Ref","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaci.2004.06.036","volume":"114","author":"RA Covar","year":"2004","unstructured":"Covar RA, Spahn JD, Martin RJ, Silkoff PE, Sundstrom DA, Murphy J, Szefler SJ (2004) Safety and application of induced sputum analysis in childhood asthma. J Allergy Clin Immunol 114:575-582","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR29_Ref","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-111-7-592","volume":"111","author":"R Dillman","year":"1989","unstructured":"Dillman R (1989) Monoclonal antibodies for treating cancer. Ann Intern Med 111:592-603","journal-title":"Ann Intern Med"},{"key":"12_CR30_Ref","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1378\/chest.130.2.429","volume":"130","author":"AE Dixon","year":"2006","unstructured":"Dixon AE, Kaminsky DA, Holbrook JT, Wise RA, Shade DM, Irvin CG (2006) Allergic rhinitis and sinusitis in asthma: Differential effects on symptoms and pulmonary function. Chest 130:429-435","journal-title":"Chest"},{"key":"12_CR31_Ref","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","volume":"170","author":"R Djukanovic","year":"2004","unstructured":"Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, Bao W, Fowler-Taylor A, Matthews J, Busse WW, Holgate ST, Fahy JV (2004) Effects of treatment with antiimmunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR32_Ref","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S1081-1206(10)61707-3","volume":"92","author":"C Dolan","year":"2004","unstructured":"Dolan C, Fraher K, Bleecker E, Borish LC, B, Hayden M, Weiss S, Zheng B, Johnson C, Wenzel S (2004) Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 92:32-39","journal-title":"Ann Allergy Asthma Immunol"},{"key":"12_CR33_Ref","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0091-6749(73)90119-X","volume":"52","author":"J Dolovich","year":"1973","unstructured":"Dolovich J, Hargreave FE, Chalmers R, Shier KJ, Gauldie J, Bienenstock J (1973) Late cutaneous allergic responses in isolated IgE-dependent reactions. J Allergy Clin Immunol 52:38-46","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR34_Ref","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMra054308","volume":"355","author":"W Eder","year":"2006","unstructured":"Eder W, Ege MJ, von Mutius E (2006) The asthma epidemic. N Engl J Med 355:2226-2235","journal-title":"N Engl J Med"},{"key":"12_CR35_Ref","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/rccm.200601-072OC","volume":"174","author":"EM Erin","year":"2006","unstructured":"Erin EM, Leaker BR, Nicholson GC, Tan AJ, Green LM, Neighbour H, Zacharasiewicz AS, Turner J, Barnathan ES, Kon OM, Barnes PJ, Hansel TT (2006) The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit. Care Med 174:753-762","journal-title":"Am J Respir Crit. Care Med"},{"key":"12_CR36_Ref","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMe058266","volume":"354","author":"SC Erzurum","year":"2006","unstructured":"Erzurum SC (2006) Inhibition of tumor necrosis factor \u03b1 for refractory asthma. N Engl J Med 354:754-758","journal-title":"N Engl J Med"},{"key":"12_CR37_Ref","doi-asserted-by":"crossref","unstructured":"Fahy J, Cockcroft D, Boulet L, Wong H, Deschesnes F, Dvid E, Ruppel J, Su J, Adelman D (1999) Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 160","DOI":"10.1164\/ajrccm.160.3.9810012"},{"key":"12_CR38_Ref","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","volume":"155","author":"JV Fahy","year":"1997","unstructured":"Fahy JV, Fleming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Boushey HA (1997) The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155:1828-1834","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR39_Ref","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1172\/JCI17974","volume":"112","author":"P Flood-Page","year":"2003a","unstructured":"Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB (2003a) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112:1029-1036","journal-title":"J Clin Invest"},{"key":"12_CR40_Ref","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","volume":"167","author":"PT Flood-Page","year":"2003b","unstructured":"Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS (2003b) Eosinophil\u2019s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167:199-204","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR41_Ref","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0091-6749(00)90190-8","volume":"105","author":"E Geiger","year":"2000","unstructured":"Geiger E, Magerstaedt R, Weendorf JHM, Kraft S, Hanau D, Bieber T (2000) IL-4 induces the intracellular expression of the \u03b1 chain of the high-affinity receptor for IgE in in vitro-generated dendritic cells. J Allergy Clin Immunol 105:150-156","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR42_Ref","volume-title":"Briefing document on safety of omalizumab (Xolair) for treatment of allergic asthma (BLA STN 103976\/0)","author":"Genentech-Inc","year":"2003","unstructured":"Genentech-Inc (2003) Briefing document on safety of omalizumab (Xolair) for treatment of allergic asthma (BLA STN 103976\/0). Food and Drug Administration, Washington, DC"},{"key":"12_CR43_Ref","unstructured":"Genentech (2003) Omalizumab prescribing information. South San Francisco, CA"},{"key":"12_CR44_Ref","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0885066604267854","volume":"19","author":"JT Giles","year":"2004","unstructured":"Giles JT, Bathon JM (2004) Serious Infections Associated with Anticytokine Therapies in the Rheumatic Diseases. J Intensive Care Med 19:320-334","journal-title":"J Intensive Care Med"},{"key":"12_CR45_Ref","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.publhealth.26.021304.144528","volume":"26","author":"DR Gold","year":"2005","unstructured":"Gold DR, Wright R (2005) Population disparities in asthma. Ann Rev Public Health 26:89-113","journal-title":"Ann Rev Public Health"},{"key":"12_CR46_Ref","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0091-6749(91)90149-I","volume":"88","author":"P Gosset","year":"1991","unstructured":"Gosset P, Tsicopoulos A, Wallaert B, Vannimenus C, Joseph M, Tonnel A-B, Capron A (1991) Increased secretion of tumor necrosis factor \u03b1 and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 88:561-571","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR47_Ref","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","volume":"282","author":"G Grunig","year":"1998","unstructured":"Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB (1998) Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261-2263","journal-title":"Science"},{"key":"12_CR48_Ref","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.iac.2005.04.001","volume":"25","author":"T Gulliver","year":"2005","unstructured":"Gulliver T, Eid N (2005) Effects of glucocorticoids on the hypothalamic-pituitary-adrenal axis in children and adults. Immunol Allergy Clin North Am 25:541-555","journal-title":"Immunol Allergy Clin North Am"},{"key":"12_CR49_Ref","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1183\/09031936.02.00283402","volume":"19","author":"T Hajiro","year":"2002","unstructured":"Hajiro T, Nishimura K (2002) Minimal clinically significant difference in health status: the thorny path of health status measures? Eur Respir J 19:390-391","journal-title":"Eur Respir J"},{"key":"12_CR50_Ref","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0091-6749(99)70326-X","volume":"104","author":"H Hakonarson","year":"1999","unstructured":"Hakonarson H, Carter C, Kim C, Grunstein M (1999) Altered expression and action of the low-affinity IgE receptor Fc\u03b5RII (CD23) in asthmatic airway smooth muscle. J Allergy Clin Immunol 104:575-584","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR51_Ref","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.iac.2004.09.006","volume":"25","author":"Harding","year":"2005","unstructured":"Harding (2005) Gastroesophageal reflux: a potential asthma trigger. Immunol Allergy Clin N Am 25:131-148","journal-title":"Immunol Allergy Clin N Am"},{"key":"12_CR52_Ref","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.semarthrit.2004.11.006","volume":"34","author":"MC Hochberg","year":"2005","unstructured":"Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE (2005) The benefit\/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34:819-836","journal-title":"Semin Arthritis Rheum"},{"key":"12_CR53_Ref","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","volume":"19","author":"G Hochhaus","year":"2003","unstructured":"Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y (2003) Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19:491-498","journal-title":"Curr Med Res Opin"},{"key":"12_CR54_Ref","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","volume":"34","author":"ST Holgate","year":"2004","unstructured":"Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD (2004) Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34:632-638","journal-title":"Clin Exp Allergy"},{"key":"12_CR55_Ref","doi-asserted-by":"crossref","first-page":"B12","DOI":"10.1038\/35037009","volume":"402","author":"P Holt","year":"1999","unstructured":"Holt P, Macaubas C, Stumbles P, Sly P (1999) The role of allergy in the development of asthma. Nature 402:B12-B17","journal-title":"Nature"},{"key":"12_CR56_Ref","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/thx.2005.045260","volume":"60","author":"PH Howarth","year":"2005","unstructured":"Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, Reynolds A, Davies DE, Holgate ST (2005) Tumour necrosis factor (TNF\u03b1 ) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60:1012-1018","journal-title":"Thorax"},{"key":"12_CR57_Ref","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","volume":"60","author":"M Humbert","year":"2005","unstructured":"Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K (2005) Benefits of omalizumab as addon therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309-316","journal-title":"Allergy"},{"key":"12_CR58_Ref","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0091-6749(97)70028-9","volume":"99","author":"M Humbert","year":"1997","unstructured":"Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, Menz G, Kay AB, Corrigan CJ (1997) Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 99:657-665","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR59_Ref","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1067\/mpd.2000.107161","volume":"137","author":"JS Hyams","year":"2000","unstructured":"Hyams JS, Markowitz J, Wyllie R (2000) Use of infliximab in the treatment of Crohn\u2019s disease in children and adolescents. J Pediatr 137:192-196","journal-title":"J Pediatr"},{"key":"12_CR60_Ref","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/02770900600566892","volume":"43","author":"S Jain","year":"2006","unstructured":"Jain S, Bandi V, Officer T, Wolley M, Guntupalli K (2006) Role of vocal cord function and dysfunction in patients presenting with symptoms of acute asthma exacerbation. J Asthma 43:207-212","journal-title":"J Asthma"},{"key":"12_CR61_Ref","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1067\/mai.2000.107604","volume":"105","author":"H Jiang","year":"2000","unstructured":"Jiang H, Harris MB, Rothman P (2000) IL-4\/IL-13 signaling beyond JAK\/STAT. J Allergy Clin Immunol 105:1063-1070","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR62_Ref","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1183\/09031936.02.00063702","volume":"19","author":"PW Jones","year":"2002","unstructured":"Jones PW (2002) Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 19:398-404","journal-title":"Eur Respir J"},{"key":"12_CR63_Ref","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00063198-199903000-00005","volume":"5","author":"E Juniper","year":"1999","unstructured":"Juniper E (1999) Health-related quality of life in asthma. Curr Opin Pulm Med 5:105-110","journal-title":"Curr Opin Pulm Med"},{"key":"12_CR64_Ref","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/thx.47.2.76","volume":"47","author":"E Juniper","year":"1992","unstructured":"Juniper E, Guyatt G, Epstein R, Ferrie P, Jaeschke R, Hiller T (1992) Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47:76-83","journal-title":"Thorax"},{"key":"12_CR65_Ref","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1 -neutralizing agent. N Engl J Med 345:1098-1104","journal-title":"N Engl J Med"},{"key":"12_CR66_Ref","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1164\/ajrccm.155.2.9032192","volume":"155","author":"VM Keatings","year":"1997","unstructured":"Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155:542-548","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR67_Ref","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2222.2005.02407.x","volume":"36","author":"J Kim","year":"2006","unstructured":"Kim J, McKinley L, Natarajan S, Bolgos GL, Siddiqui J, Copeland S, Remick DG (2006) Anti-tumor necrosis factor-alpha antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust. Clin Exp Allergy 36:122-132","journal-title":"Clin Exp Allergy"},{"key":"12_CR68_Ref","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","volume":"167","author":"JC Kips","year":"2003","unstructured":"Kips JC, O\u2019Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167:1655-1659","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR69_Ref","doi-asserted-by":"crossref","first-page":"12911","DOI":"10.1073\/pnas.1735525100","volume":"100","author":"J Kitaura","year":"2003","unstructured":"Kitaura J, Song J, Tsai M, Asai K, Maeda-Yamamoto M, Mocsai A, Kawakami Y, Liu F-T, Lowell CA, Barisas BG, Galli SJ, Kawakami T (2003) Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the Fc\u03b5RI. PNAS 100:12911-12916","journal-title":"PNAS"},{"key":"12_CR70_Ref","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1183\/09031936.96.09050899","volume":"9","author":"C Kroegel","year":"1996","unstructured":"Kroegel C, Julius P, Matthys H, Virchow Jc, Jr., Luttmann W (1996) Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 9:899-904","journal-title":"Eur Respir J"},{"key":"12_CR71_Ref","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","volume":"42","author":"S Kroesen","year":"2003","unstructured":"Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-\u03b1 therapy. Rheumatology 42:617-621","journal-title":"Rheumatology"},{"key":"12_CR72_Ref","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1067\/mai.2002.121949","volume":"109","author":"J Kuehr","year":"2002","unstructured":"Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann K-C, Rolinck-Werninghaus C, Grave M (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109:274-280","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR73_Ref","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1084\/jem.139.3.600","volume":"139","author":"A Kulczycki","year":"1974","unstructured":"Kulczycki A, Isersky C, Metzger H (1974) The interaction of IgE with rat basophilic leukemia cells. I. Evidence for specific binding of IgE. J Exp Med 139:600-616","journal-title":"J Exp Med"},{"key":"12_CR74_Ref","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","volume":"356","author":"MJ Leckie","year":"2000","unstructured":"Leckie MJ, Brinke At, Khan J, Diamant Z, O\u2019Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356:2144-2148","journal-title":"Lancet"},{"key":"12_CR75_Ref","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1542\/peds.110.5.e55","volume":"110","author":"RF Lemanske Jr.","year":"2002","unstructured":"Lemanske RF, Jr., Nayak A, McAlary M, Everhard F, Fowler-Taylor A, Gupta N (2002) Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 110:e55","journal-title":"Pediatrics"},{"key":"12_CR76_Ref","doi-asserted-by":"crossref","unstructured":"Leung DYM, Sampson HA, Yunginger JW, Burks AW, Jr., Schneider LC, Wortel CH, Davis FM, Hyun JD, Shanahan WR, Jr., the TNXPASG (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348:986-993","DOI":"10.1056\/NEJMoa022613"},{"key":"12_CR77_Ref","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.200508-1256OC","volume":"173","author":"Y-F Li","year":"2006","unstructured":"Li Y-F, Gauderman WJ, Avol E, Dubeau L, Gilliland FD (2006) Associations of tumor necrosis factor G-308A with childhood asthma and wheezing. Am J Respir Crit Care Med 173:970-976","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR78_Ref","doi-asserted-by":"crossref","first-page":"10474","DOI":"10.1021\/bi00033a020","volume":"34","author":"J Liu","year":"1995","unstructured":"Liu J, Lester P, Builder S, Shire SJ (1995) Characterization of Complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 34:10474-10482","journal-title":"Biochemistry"},{"key":"12_CR79_Ref","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2005.10.006","volume":"27","author":"NL Lugogo","year":"2006","unstructured":"Lugogo NL, Kraft M (2006) Epidemiology of asthma. Clin Chest Med 27:1-15","journal-title":"Clin Chest Med"},{"key":"12_CR80_Ref","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0091-6749(93)90266-I","volume":"91","author":"D MacGlashan","year":"1993","unstructured":"MacGlashan D (1993) Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 91:605-615","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR81_Ref","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","volume":"158","author":"DW MacGlashan Jr.","year":"1997","unstructured":"MacGlashan DW, Jr., Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM (1997) Down-regulation of Fc\u03b5RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 158:1438-1445","journal-title":"J Immunol"},{"key":"12_CR82_Ref","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1172\/JCI109103","volume":"62","author":"F Malveaux","year":"1978","unstructured":"Malveaux F, Conroy M, Adkinson NJ, LM L (1978) IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest 62:176-181","journal-title":"J Clin Invest"},{"key":"12_CR83_Ref","unstructured":"Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC (2000) Surveillance for Asthma - United States, 1980-1999."},{"key":"12_CR84_Ref","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.129.2.466","volume":"129","author":"P Marcus","year":"2006","unstructured":"Marcus P (2006) Incorporating anti-IgE (omalizumab) therapy into pulmonary medicine practice: practice management implications. Chest 129:466-474","journal-title":"Chest"},{"key":"12_CR85_Ref","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJM199501193320301","volume":"332","author":"FD Martinez","year":"1995","unstructured":"Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ (1995) Asthma and wheezing in the first six years of life. N Engl J Med 332:133-138","journal-title":"N Engl J Med"},{"key":"12_CR86_Ref","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.4049\/jimmunol.154.12.6285","volume":"154","author":"D Maurer","year":"1995","unstructured":"Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G (1995) The high affinity IgE receptor (Fc\u03b5RI) mediates IgE-dependent allergen presentation. J Immunol 154:6285-6290","journal-title":"J Immunol"},{"key":"12_CR87_Ref","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1542\/peds.108.2.e36","volume":"108","author":"H Milgrom","year":"2001","unstructured":"Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P (2001) Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 108:e36","journal-title":"Pediatrics"},{"key":"12_CR88_Ref","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","volume":"341","author":"H Milgrom","year":"1999a","unstructured":"Milgrom H, Fick R, Su J, Reimann J, Bush R, Watrous M, Metzger W (1999a) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341:1966-1973","journal-title":"N Engl J Med"},{"key":"12_CR89_Ref","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","volume":"341","author":"H Milgrom","year":"1999b","unstructured":"Milgrom H, Fick RB, Su JQ, Reimann JD, Bush RK, Watrous ML, Metzger WJ, The rhu MESG (1999b) Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341:1966-1973","journal-title":"N Engl J Med"},{"key":"12_CR90_Ref","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1398-9995.2006.00983.x","volume":"61","author":"EC Mingomataj","year":"2006","unstructured":"Mingomataj EC, Xhixha F, Gjata E (2006) Helminths can protect themselves against rejection inhibiting hostile respiratory allergy symptoms. Allergy 61:400-406","journal-title":"Allergy"},{"key":"12_CR91_Ref","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1465-9921-7-125","volume":"7","author":"S Mukhopadhyay","year":"2006","unstructured":"Mukhopadhyay S, Hoidal J, Mukherjee T (2006) Role of TNF\u03b1 in pulmonary pathophysiology. Respir Res 7:125","journal-title":"Respir Res"},{"key":"12_CR92_Ref","unstructured":"NAEEP (1997) National Asthma Education and Prevention Program Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NIH"},{"key":"12_CR93_Ref","unstructured":"NAEEP (2002) Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics (2002). NIH"},{"key":"12_CR94_Ref","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0091-6749(91)92137-P","volume":"88","author":"NHLBI","year":"1991","unstructured":"NHLBI (1991) Guidelines for the Diagnosis and Management of Asthma: I. Definition and diagnosis. J Allergy Clin Immunol 88:427-438","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR95_Ref","unstructured":"NHLBI\/WHO (2002) Global Initiative for asthma: global strategy for asthma management and prevention. NIH"},{"key":"12_CR96_Ref","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaci.2004.05.049","volume":"114","author":"Y Oba","year":"2004","unstructured":"Oba Y, Salzman GA (2004) Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 114:265-269","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR97_Ref","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.gene.6364284","volume":"7","author":"C Ober","year":"2006","unstructured":"Ober C, Hoffjan S (2006) Asthma genetics 2006: the long and winding road to gene discovery. Genes Immunol 7:95-100","journal-title":"Genes Immunol"},{"key":"12_CR98_Ref","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1067\/mai.2001.113759","volume":"107","author":"HC Oettgen","year":"2001","unstructured":"Oettgen HC, Geha RS (2001) IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 107:429-440","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR99_Ref","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1165\/ajrcmb.16.5.9160833","volume":"16","author":"Y Ohkawara","year":"1997","unstructured":"Ohkawara Y, Lei XF, Stampfli MR, Marshall JS, Xing Z, Jordana M (1997) Cytokine and eosinophil responses in the lung, peripheral blood, and bone marrow compartments in a murine model of allergen-induced airways inflammation. Am J Respir Cell Mol Biol 16:510-520","journal-title":"Am J Respir Cell Mol Biol"},{"key":"12_CR100_Ref","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaci.2005.05.035","volume":"116","author":"YE Ong","year":"2005","unstructured":"Ong YE, Menzies-Gow A, Barkans J, Benyahia F, Ou T-T, Ying S, Kay AB (2005) Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116:558-564","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR101_Ref","first-page":"33","volume":"27","author":"KW Parks","year":"2006","unstructured":"Parks KW, Casale TB (2006) Anti-immunoglobulin E monoclonal antibody administered with immunotherapy. Allergy Asthma Proc 27:33-36","journal-title":"Allergy Asthma Proc"},{"key":"12_CR102_Ref","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1183\/09031936.98.12010045","volume":"12","author":"HJ Pennings","year":"1998","unstructured":"Pennings HJ, Kramer K, Bast A, Buurman WA, Wouters EF (1998) Tumour necrosis factor-alpha induces hyperreactivity in tracheal smooth muscle of the guinea-pig in vitro. Eur Respir J 12:45-49","journal-title":"Eur Respir J"},{"key":"12_CR103_Ref","doi-asserted-by":"crossref","first-page":"26368","DOI":"10.1016\/S0021-9258(18)47203-1","volume":"269","author":"L Presta","year":"1994","unstructured":"Presta L, Shields R, O\u2019Connell L, Lahr S, Porter J, Gorman C, Jardieu P (1994) The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269:26368-26373","journal-title":"J Biol Chem"},{"key":"12_CR104_Ref","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.151.5.2623","volume":"151","author":"LG Presta","year":"1993","unstructured":"Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993) Humanization of an antibody directed against IgE. J Immunol 151:2623-2632","journal-title":"J Immunol"},{"key":"12_CR105_Ref","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","volume":"112","author":"C Prussin","year":"2003","unstructured":"Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB (2003) Omalizumab treatment downregulates dendritic cell Fc\u03b5RI expression. J Allergy Clin Immunol 112:1147-1154","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR106_Ref","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.1016\/j.jaci.2005.11.016","volume":"117","author":"C Prussin","year":"2006","unstructured":"Prussin C, Metcalfe DD (2006) IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 117:S450-S456","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR107_Ref","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJM199810083391503","volume":"339","author":"F Qureshi","year":"1998","unstructured":"Qureshi F, Pestian J, Davis P, Zaritsky A (1998) Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 339:1030-1035","journal-title":"N Engl J Med"},{"key":"12_CR108_Ref","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1542\/peds.2005-2000I","volume":"117","author":"MJ Reeves","year":"2006","unstructured":"Reeves MJ, Bohm SR, Korzeniewski SJ, Brown MD (2006) Asthma care and management before an emergency department visit in children in Western Michigan: how well does care adhere to guidelines? Pediatrics 117:S118-126","journal-title":"Pediatrics"},{"key":"12_CR109_Ref","volume-title":"FDA medical officer\u2019s review of safety information on omalizumab in briefing BLA STN 103976\/0","author":"D Rieves","year":"2003","unstructured":"Rieves D (2003) FDA medical officer\u2019s review of safety information on omalizumab in briefing BLA STN 103976\/0. Food and Drug Administration, Washington, DC"},{"key":"12_CR110_Ref","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1183\/09031936.06.00003706","volume":"28","author":"NJ Roberts","year":"2006","unstructured":"Roberts NJ, Robinson DS, Partridge MR (2006) How is difficult asthma managed? Eur Respir J 28:968-973","journal-title":"Eur Respir J"},{"key":"12_CR111_Ref","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ddr.10346","volume":"61","author":"LK Roskos","year":"2004","unstructured":"Roskos LK, Davis CG, Schwab GM (2004) The clinical pharmacology of therapeutic monoclonal antibodies. Drug Development Res 61:108-120","journal-title":"Drug Development Res"},{"key":"12_CR112_Ref","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1592\/phco.2005.25.9.1181","volume":"25","author":"D Rychly","year":"2005","unstructured":"Rychly D, DiPiro J (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25:1181-1192","journal-title":"Pharmacotherapy"},{"key":"12_CR113_Ref","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.4049\/jimmunol.162.9.5624","volume":"162","author":"SS Saini","year":"1999","unstructured":"Saini SS, MacGlashan DW, Jr., Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, Bochner BS (1999) Down-regulation of human basophil IgE and FC\u03b5RI\u03b1 surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162:5624-5630","journal-title":"J Immunol"},{"key":"12_CR114_Ref","doi-asserted-by":"crossref","first-page":"6S","DOI":"10.1164\/ajrccm.164.supplement_1.2103025","volume":"164","author":"ES Schulman","year":"2001","unstructured":"Schulman ES (2001) Development of a monoclonal anti-immunoglobulin E antibody (Omalizumab) for the treatment of allergic respiratory disorders. Am J Respir Crit Care Med 164:6S-11","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR115_Ref","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMct055183","volume":"355","author":"DL Scott","year":"2006","unstructured":"Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704-712","journal-title":"N Engl J Med"},{"key":"12_CR116_Ref","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000237010","volume":"107","author":"R Shields","year":"1995","unstructured":"Shields R, Whether W, Zioncheck K, O\u2019Connell L, Fendly B, Presta L, Thomas D, Saban R, Jardieu P (1995) Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 107:308-312","journal-title":"Int Arch Allergy Immunol"},{"key":"12_CR117_Ref","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1081-1206(10)60907-6","volume":"96","author":"RG Slavin","year":"2006","unstructured":"Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE (2006) Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy, Asthma Immunol 96:406-414","journal-title":"Ann Allergy, Asthma Immunol"},{"key":"12_CR118_Ref","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","volume":"18","author":"M Soler","year":"2001","unstructured":"Soler M, Matz J, Townley R, Buhl R, O\u2019Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18:254-261","journal-title":"Eur Respir J"},{"key":"12_CR119_Ref","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1056\/NEJM199008233230802","volume":"323","author":"R Sporik","year":"1990","unstructured":"Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ (1990) Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 323:502-507","journal-title":"N Engl J Med"},{"key":"12_CR120_Ref","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMct055184","volume":"354","author":"RC Strunk","year":"2006","unstructured":"Strunk RC, Bloomberg GR (2006) Omalizumab for Asthma. N Engl J Med 354:2689-2695","journal-title":"N Engl J Med"},{"key":"12_CR121_Ref","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2003.08.014","volume":"112","author":"RC Strunk","year":"2003","unstructured":"Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske JRF (2003) Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol 112:883-892","journal-title":"J Allergy Clin Immunol"},{"key":"12_CR122_Ref","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/thorax.57.9.774","volume":"57","author":"P Thomas","year":"2002","unstructured":"Thomas P, Heywood G (2002) Effects of inhaled tumour necrosis factor alpha in subjects with mild asthma. Thorax 57:774-778","journal-title":"Thorax"},{"key":"12_CR123_Ref","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1164\/ajrccm.152.1.7599866","volume":"152","author":"PS Thomas","year":"1995","unstructured":"Thomas PS, Yates DH, Barnes PJ (1995) Tumor necrosis factor-alpha increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med 152:76-80","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR124_Ref","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1046\/j.1440-1843.2003.00465.x","volume":"8","author":"JW Upham","year":"2003","unstructured":"Upham JW (2003) The role of dendritic cells in immune regulation and allergic airway inflammation. Respirology 8:140-148","journal-title":"Respirology"},{"key":"12_CR125_Ref","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1164\/rccm.200501-147OC","volume":"172","author":"H van der Vaart","year":"2005","unstructured":"van der Vaart H, Koeter GH, Postma DS, Kauffman HF, ten Hacken NHT (2005) First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 172:465-469","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR126_Ref","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","volume":"59","author":"AM Vignola","year":"2004","unstructured":"Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K (2004) Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 59:709-717","journal-title":"Allergy"},{"key":"12_CR127_Ref","doi-asserted-by":"crossref","unstructured":"Walker S, Monteil M, Phelan K, Lasserson T, EHW (2006) Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev","DOI":"10.1002\/14651858.CD003559.pub3"},{"key":"12_CR128_Ref","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2174\/1381612054864984","volume":"11","author":"GM Walsh","year":"2005","unstructured":"Walsh GM (2005) Novel therapies for asthma - advances and problems. Curr Pharm Design 11:3027-3038","journal-title":"Curr Pharm Design"},{"key":"12_CR129_Ref","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.2174\/092986706778201594","volume":"13","author":"GM Walsh","year":"2006","unstructured":"Walsh GM (2006) Targeting airway inflammation: novel therapies for the treatment of asthma. Curr Med Chem 13:3105-3111","journal-title":"Curr Med Chem"},{"key":"12_CR130_Ref","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1378\/chest.119.4.1034","volume":"119","author":"HAH Wijnhoven","year":"2001","unstructured":"Wijnhoven HAH, Kriegsman DMW, Hesselink AE, Penninx BWJH, de Haan M (2001) Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and health-related quality of life. Chest 119:1034-1042","journal-title":"Chest"},{"key":"12_CR131_Ref","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1126\/science.282.5397.2258","volume":"282","author":"M Wills-Karp","year":"1998","unstructured":"Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD (1998) Interleukin-13: central mediator of allergic asthma. Science 282:2258-2261","journal-title":"Science"},{"key":"12_CR132_Ref","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","volume":"167","author":"KL Wood","year":"2003","unstructured":"Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, Wheat LJ, Twigg HL, III (2003) Histoplasmosis after Treatment with Anti-Tumor Necrosis Factor-\u03b1 Therapy. Am J Respir Crit Care Med 167:1279-1282","journal-title":"Am J Respir Crit Care Med"},{"key":"12_CR133_Ref","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1471-4906(01)01958-5","volume":"22","author":"M Yazdanbakhsh","year":"2001","unstructured":"Yazdanbakhsh M, van den Biggelaar A, Maizels RM (2001) Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease. Trends Immunol 22:372-377","journal-title":"Trends Immunol"},{"key":"12_CR134_Ref","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1081\/JAS-120023577","volume":"40","author":"M Yigla","year":"2003","unstructured":"Yigla M, Tov N, Solomonov A, Rubin A, Harlev D (2003) Difficult-to-control asthma and obstructive sleep apnea. J Asthma 40:865-871","journal-title":"J Asthma"}],"container-title":["Handbook of Experimental Pharmacology","Therapeutic Antibodies"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-540-73259-4_12.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T06:57:41Z","timestamp":1684133861000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-540-73259-4_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"ISBN":["9783540732587","9783540732594"],"references-count":134,"URL":"https:\/\/doi.org\/10.1007\/978-3-540-73259-4_12","relation":{},"ISSN":["0171-2004"],"issn-type":[{"value":"0171-2004","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}